TLR9 and neoplasm: By delivering an adjuvant (the TLR9 ligand CpG deoxynucleotides or the TLR3 ligand poly-IC) to immune cells (macrophages and dendritic cells) localized in tumor tissue using nanogels, the tumor microenvironment is immunologically activated to enhance the antitumor effect [11].